Historical Valuation
Amgen Inc (AMGN) is now in the Fair zone, suggesting that its current forward PE ratio of 15.47 is considered Fairly compared with the five-year average of 14.04. The fair price of Amgen Inc (AMGN) is between 320.68 to 358.24 according to relative valuation methord.
Relative Value
Fair Zone
320.68-358.24
Current Price：330.41
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Amgen Inc (AMGN) has a current Price-to-Book (P/B) ratio of 18.34. Compared to its 3-year average P/B ratio of 24.41 , the current P/B ratio is approximately -24.86% higher. Relative to its 5-year average P/B ratio of 30.66, the current P/B ratio is about -40.17% higher. Amgen Inc (AMGN) has a Forward Free Cash Flow (FCF) yield of approximately 6.54%. Compared to its 3-year average FCF yield of 5.76%, the current FCF yield is approximately 13.63% lower. Relative to its 5-year average FCF yield of 6.11% , the current FCF yield is about 7.04% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for AMGN competitors is 7.26, providing a benchmark for relative valuation. Amgen Inc Corp (AMGN.O) exhibits a P/S ratio of 4.79, which is -33.98% above the industry average. Given its robust revenue growth of 12.40%, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of AMGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AMGN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AMGN currently overvalued or undervalued?
Amgen Inc (AMGN) is now in the Fair zone, suggesting that its current forward PE ratio of 15.47 is considered Fairly compared with the five-year average of 14.04. The fair price of Amgen Inc (AMGN) is between 320.68 to 358.24 according to relative valuation methord.
What is Amgen Inc (AMGN) fair value?
AMGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Amgen Inc (AMGN) is between 320.68 to 358.24 according to relative valuation methord.
How does AMGN's valuation metrics compare to the industry average?
The average P/S ratio for AMGN's competitors is 7.26, providing a benchmark for relative valuation. Amgen Inc Corp (AMGN) exhibits a P/S ratio of 4.79, which is -33.98% above the industry average. Given its robust revenue growth of 12.40%, this premium appears unsustainable.
What is the current P/B ratio for Amgen Inc (AMGN) as of Jan 18 2026?
As of Jan 18 2026, Amgen Inc (AMGN) has a P/B ratio of 18.34. This indicates that the market values AMGN at 18.34 times its book value.
What is the current FCF Yield for Amgen Inc (AMGN) as of Jan 18 2026?
As of Jan 18 2026, Amgen Inc (AMGN) has a FCF Yield of 6.54%. This means that for every dollar of Amgen Inc’s market capitalization, the company generates 6.54 cents in free cash flow.
What is the current Forward P/E ratio for Amgen Inc (AMGN) as of Jan 18 2026?
As of Jan 18 2026, Amgen Inc (AMGN) has a Forward P/E ratio of 15.47. This means the market is willing to pay $15.47 for every dollar of Amgen Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Amgen Inc (AMGN) as of Jan 18 2026?
As of Jan 18 2026, Amgen Inc (AMGN) has a Forward P/S ratio of 4.79. This means the market is valuing AMGN at $4.79 for every dollar of expected revenue over the next 12 months.